共查询到20条相似文献,搜索用时 500 毫秒
1.
基于代谢组学的细胞内源性代谢物研究进展 总被引:1,自引:0,他引:1
代谢组学是继基因组学、转录组学和蛋白质组学之后新兴的一种定性和定量分析复杂生物样品中所有小分子代谢物的组学方法,也是目前组学研究领域的热点之一。代谢组学主要考察生物体系受刺激或扰动后内源性代谢物的变化,是系统生物学的有机组成部分。近年来在代谢组学研究中,细胞内源性代谢物的研究已取得了很大进展。本文结合代谢组学的基本含义,综述了细胞样品前处理方法及代谢靶向分析、代谢轮廓分析、代谢组学分析和代谢足迹分析在细胞方面的研究进展。 相似文献
2.
目的 研究栝楼桂枝汤对脑缺血MCAO模型大鼠的神经保护作用机制。方法 运用气相色谱-飞行时间质谱联用的代谢组学技术及多元统计分析方法分析正常组、模型组和栝楼桂枝汤给药组大鼠血清中内源性代谢物的变化,筛选差异代谢物,并分析差异代谢物代谢途径。结果 代谢组学研究结果显示各组间大鼠代谢谱出现显著差异,在大鼠血清质谱图中共筛选鉴定得吲哚乙酸、丙二酸、乙醇胺、肉豆蔻酸、鸟氨酸等13个差异代谢物,涉及的相关的代谢途径包括糖-葡萄糖醛酸相互转化途径,色氨酸代谢途径,嘧啶代谢和甘油磷脂代谢途径。结论 栝楼桂枝汤可使造模后大鼠的体内代谢物有不同程度的恢复,其对缺血性脑卒中的保护作用主要反映在能量代谢、脂质代谢、氨基酸代谢等代谢途径的变化,改善大鼠脑缺血再灌注损伤症状。 相似文献
3.
4.
代谢组学是系统生物学的重要组成部分。研究显示,代谢组学在临床诊断过程中有着不可比拟的作用。当机体受到外源性或内源性刺激时,体内小分子代谢物的种类及含量会发生显著改变,代谢组学技术通过对体内复杂代谢物的动态变化进行分析,分析代谢物变化与机体病理或生理变化的直接相关性。随着分析技术的不断发展,核磁共振、色谱-质谱联用等先进技术被广泛应用于代谢组学的研究中。目前临床运用代谢组学技术可以全面分析患者体液中代谢物的动态变化,发现体液中与疾病密切相关的特征性生物标志物,从而实现疾病的早期临床诊断。本文主要对代谢组学技术及其在临床诊断过程中的广泛应用作一综述。 相似文献
5.
6.
7.
中药复方作为中医临床用药最广泛的形式,其药效物质基础和作用机制的科学阐释成为全面揭示中医药实用价值进而实现中药现代化的关键。代谢组学技术始于20世纪90年代中期,旨在利用现代科学技术研究生物体系在受到刺激或干扰后,内源性代谢物组的变化或随时间的变化规律,以代谢物组分析为基础,借助高通量检测和多元化数据处理手段,整合多维生物信息系统,阐明中药复方的药效物质基础和作用机制。综述了最新代谢组学技术的研究进展及在中药复方药效物质基础和作用机制研究中的应用情况,并对代谢组学技术未来发展趋势进行展望。 相似文献
8.
代谢组学是定性及定量描述内源性代谢物变化的科学,正广泛应用于疾病诊断和预后过程中。血液和尿液是代谢组学研究中常用的生物样本,但因其代谢物繁多、成分复杂,亟须使用灵敏度高、特异性强的分离分析技术。液相色谱-质谱联用(liquid chromatography-mass spectrometry, LC-MS)技术分析速度快、分离效率高,非常适用于代谢组学等方面的研究。生物样本的采集、处理过程是实验中最关键的一步,直接决定着实验结果的准确性,因此生物样本预处理过程的标准化显得尤为重要。本文综述了常用的生物流体—血液和尿液的收集、处理及储存方法,以期为有关代谢组学研究提供参考。 相似文献
9.
摘要:代谢组学具有灵敏、快速、高通量的特点,在研究内源性小分子的变化规律、发现异常代谢物、揭示个体代谢表征等方面具有应用潜力。利用代谢组学研究高尿酸血症合并慢性肾脏疾病是近年来的热点。对高尿酸血症合并慢性肾脏疾病的相关代谢组学的研究表明,该病与氨基酸、脂质代谢紊乱密切相关。就代谢组学在高尿酸血症合并慢性肾脏疾病发病机制探索、生物标志物筛选、中药治疗方面的应用展开综述。 相似文献
10.
代谢组学是“后基因组学”时期的一门新兴学科,其同基因组学、转录组学、蛋白质组学共同构成了系统生物学的核心内容。代谢组学对生物体系在生理或病理状态下所有内源性小分子代谢产物的动态变化进行分析,从而探索内源性小分子物质与疾病发生发展间的关系。目前,代谢组学被广泛应用于肿瘤标志物筛选、疾病诊断、新药研究与开发等多个领域。近年来,国内外学者通过代谢组学技术分析了乳腺癌患者的代谢物轮廓特征,筛选出有价值的潜在标志物,为乳腺癌的预防、早期诊断和个体化治疗开辟了新途径。本文针对这些乳腺癌潜在代谢标志物进行综述。 相似文献
11.
12.
目的分析血浆血栓素B2(TXB2)及6-酮-前列腺素F1a(6-keto—PGF1a)与进展性缺血性脑卒中早期进展的相关性及临床意义。方法检测患者及健康对照组外周血血浆TXB2及6-keto—PGF1a水平,分析其在缺血性卒中组、进展性缺血性卒中组与健康对照组水平的差异。结果缺血性脑卒中组血浆TXB2、血浆血栓素B2/血浆6-酮-前列腺素F1a(T/P)比值高于健康对照组,6-keto—PGF1a低于健康对照组,有统计学意义(P〈0.05);进展性缺血性卒中组血浆TXB2、T/P高于非进展性缺血性卒中组,6-keto—PGF1a低于非进展性缺血性卒中组,有统计学意义(P〈0.05)。结论TXB2、6-keto—PGF1a不仅参与缺血性卒中后急性期反应,而且与进展性缺血性卒中密切相关,可以作为进展性缺血性卒中的预警因子。 相似文献
13.
目的 观察血浆同型半胱氨酸(Hcy)水平与中青年脑梗死的关系,探讨Hcy在中青年脑梗死发生、发展中的临床意义.方法 应用循环酶法测定132例中青年脑梗死患者(观察组)及86例健康对照者的血浆Hcy水平,并进行比较.结果 观察组的血浆Hcy水平高于对照组[(24.32±5.68)、(12.58±3.53)μmol/L],差异有统计学意义(t=17.26,P<0.01).血浆Hcy水平越高,急性期脑梗死的病灶越大,两者呈直线正相关关系(r =0.696,P<0.01).结论 高同型半胱氨酸血症(HH)是中青年脑梗死的危险因素,血浆Hcy水平越高,急性期脑梗死的病灶越大;血浆Hcy水平能反映脑梗死灶的大小及病情程度;对有脑血管病倾向的中青年,血浆Hcy检查应作为常规检查或作为病情监测和预后判断的重要指标. 相似文献
14.
近年来,神经炎症在缺血性脑卒中中的作用引起广泛关注,小胶质细胞、星形胶质细胞及众多炎性因子参与了炎症反应,并涉及到多种炎症反应的信号通路。根据缺血性脑卒中神经炎症反机制可采取具有抗炎作用的药物治疗,包括非甾体类抗炎药、抗生素类、天然植物源抗炎药、血清蛋白酶抑制剂、他汀类、棉籽油等多种抗炎药物。就缺血性脑卒中的神经炎症反应机制及相关的抗炎药物的研究进展进行综述,为进一步探索现有药物的抗炎机制及开发新型抗炎药物提供参考,并为缺血性脑卒中提供新的治疗方向。 相似文献
15.
Cherubini A Ruggiero C Morand C Lattanzio F Dell'aquila G Zuliani G Di Iorio A Andres-Lacueva C 《Current medicinal chemistry》2008,15(12):1236-1248
Acute ischemic stroke is a leading cause of death and severe disability in industrialised countries and also in many developing countries. An excessive amount of free radicals is generated during cerebral ischemia, which significantly contributes to brain damage. Therefore, an increasing interest has been devoted to the potential benefits of antioxidant compounds in ischemic stroke patients. In this review, we examined the most relevant observational studies concerning the relationship between dietary antioxidants and ischemic stroke as well as clinical trials investigating the effects of single or multiple antioxidant supplementation in the prevention or treatment of acute ischemic stroke. Furthermore, we reviewed the most promising antioxidant compounds, i.e. dehydroascorbic acid, alpha-tocotrienol, gamma-tocopherol, flavonoids, resveratrol and gingko biloba, tested in animal models of acute ischemic stroke. Finally, we carefully evaluated the reasons for the discrepancy between experimental and clinical studies, and provided recommendations to improve the translation of the results obtained in animal models to patients with acute ischemic stroke. 相似文献
16.
Maureen A. Smythe Dennis Parker Candice L. Garwood Adam Cuker Steve R. Messé 《Pharmacotherapy》2020,40(1):55-71
Patients with atrial fibrillation (AF) who suffer an acute ischemic stroke are at risk for both hemorrhagic transformation and recurrent ischemic stroke in the acute post-stroke period. Oral anticoagulants are recommended for secondary stroke prevention in patients with AF. The optimal time to initiate anticoagulant therapy after acute ischemic stroke in patients with AF is uncertain. There is concern that early initiation increases the risk of hemorrhagic transformation, whereas delayed initiation leaves the patient at risk for recurrent ischemic stroke. In this article, we provide a review of the risk of hemorrhagic transformation of acute ischemic stroke as well as review the literature and major guidelines addressing the timing of anticoagulation initiation after an acute ischemic stroke in patients with AF. Relevant articles published from 1990 to the present were identified using the PubMed and Embase databases. The majority of available literature is observational data. Large ischemic lesions, cerebral microbleeds, thrombolytic therapy, and other clinical factors may increase the risk of hemorrhagic transformation of an acute ischemic stroke. Parenteral anticoagulation within 48 hours is associated with an increased risk of hemorrhagic transformation and is not recommended. Insufficient data exist to support the safety of routine oral anticoagulant (direct oral anticoagulants or warfarin) initiation within 48 hours of an acute ischemic stroke. Direct oral anticoagulant initiation within 2 days of an acute ischemic stroke is associated with a 5% rate of hemorrhagic transformation. Infarct size and presence of hemorrhage are important factors in identifying the optimal time to initiation and should guide decisions when available. A recommended framework for patient decision making is provided. Randomized controlled trials in this area are needed to identify the optimal timing of anticoagulation initiation, and such trials are under way. 相似文献
17.
目的探讨北方农村地区高血压患者血清总胆固醇(TC)/高密度脂蛋白胆固醇(HDL-C)比值与缺血性脑卒中的关系。方法采用分层整群抽样方法于2004—2006年对辽宁省阜新县农村地区6412名(男性2805名,女性3607名)年龄≥35岁患原发性高血压病的常住人群(≥5年)进行流行病学调查和实验室检查,对血脂异常情况使用SPSS11.5软件进行统计分析。结果①缺血性脑卒中患者共330人。与非缺血性脑卒中组相比,具有较高的血压水平,TC及LDL-C水平均较高。②将TC/HDL-C比值分为<3.0、3.0~、3.5~、4.0~、≥4.5五组,随比值的增高,缺血性脑卒中的患病率显著增高。比值最高组的患病率是比值最低组的3.4倍。各组患缺血性脑卒中的危险性均高于参照组,除比值3.0~组外,各组OR值的增高均有统计学意义。结论缺血性脑卒中的患病率随TC/HDL-C比值的增高而升高。 相似文献
18.
胆固醇/高密度脂蛋白-胆固醇比值在脑梗死中的价值研究 总被引:1,自引:0,他引:1
目的:探讨胆固醇/高密度脂蛋白-胆固醇比值(TC/HDL-C比值)与脑梗死发病危险性的关系以及这一比值在脑梗死患者合并高血压或糖尿病时的变化。方法:选择197例脑梗死患者分为三组:单纯脑梗死组、合并高血压组、合并糖尿病组。58例健康者作为正常对照组,探讨这一比值的变化。结果:胆固醇(TC)水平及TC/HDL-C比值在脑梗死患者与正常对照组间有显著性差异(P<0.05);脑梗死患者的HDL-C水平较正常对照组降低,但两者差异无显著性(P>0.05);不同病例组间TC、HDL-C水平及TC/HDL-C比值无显著性差异(P>0.05)。结论:TC/HDL-C比值是脑梗死的危险因素,与高血压、糖尿病无关。 相似文献
19.
Stroke is the second leading cause of death in the world, of which about 60 % - 80 % are ischemic stroke. Ischemic stroke will inevitably cause the damage of neurons in the core area. With the increase of ischemic time, other neurons in the ischemic penumbra will also die due to the loss of " signal connection", and further lead to body dysfunction. In view of the complexity of neuronal death mechanism after ischemic stroke, understanding the action principle of death mechanism can better save ischemic penumbra neurons. This review mainly expounds several main mechanisms and potential therapeutic targets of neuronal death after ischemic stroke, so as to provide basis and help for the improvement of action mechanism research and drug development. © 2023 Publication Centre of Anhui Medical University. All rights reserved. 相似文献
20.
Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia 总被引:7,自引:0,他引:7
Ischemic stroke is a devastating disease with a complex pathophysiology. Animal modeling of ischemic stroke serves as an indispensable tool first to investigate mechanisms of ischemic cerebral injury, secondly to develop novel antiischemic regimens. Most of the stroke models are carried on rodents. Each model has its particular strengths and weaknesses. Mimicking all aspects of human stroke in one animal model is not possible since ischemic stroke is itself a very heterogeneous disorder. Experimental ischemic stroke models contribute to our understanding of the events occurring in ischemic and reperfused brain. Major approaches developed to treat acute ischemic stroke fall into two categories, thrombolysis and neuroprotection. Trials aimed to evaluate effectiveness of recombinant tissue-type plasminogen activator in longer time windows with finer selection of patients based on magnetic resonance imaging tools and trials of novel recanalization methods are ongoing. Despite the failure of most neuroprotective drugs during the last two decades, there are good chances to soon have effective neuroprotectives with the help of improved preclinical testing and clinical trial design. In this article, we focus on various rodent animal models, pathogenic mechanisms, and promising therapeutic approaches of ischemic stroke. 相似文献